Related Experiment Videos

Diazene JK-279: potential anticancer drug

M Osmak1, T Bordukalo, B Jernej

  • 1Department of Molecular Genetics, Ruder Bosković Institute, Zagreb, Croatia. osmak@rudjer.irb.hr

Anti-Cancer Drugs
|December 10, 1999
PubMed

Insights

Newly synthesized diazenecarboxamides were tested for anticancer effects. Diazene JK-279 showed significant cytotoxicity against all 10 human cancer cell lines, including drug-resistant types, indicating its potential as an anticancer drug.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Cancer Biology

Background:

  • Development of novel anticancer agents is crucial to overcome drug resistance.
  • Diazenecarboxamides represent a class of compounds with potential therapeutic applications.

Purpose of the Study:

  • To evaluate the cytotoxic effects of 10 novel diazenecarboxamides.
  • To assess the efficacy of these compounds against various human cancer cell lines, including drug-resistant variants.

Main Methods:

  • Synthesis of 10 novel diazenecarboxamide compounds.
  • Cytotoxicity assessment using a modified colorimetric MTT assay.
  • Testing on 10 human cancer cell lines: cervical, laryngeal, glioblastoma, breast, and mammary carcinoma, including parental and drug-resistant strains.

Main Results:

  • Diazene JK-279 demonstrated significant cytotoxicity against all 10 tested cell lines, including five drug-resistant ones.
  • Diazene JK-835 showed cytotoxic effects on nine out of 10 cell lines.
  • Limited cytotoxic activity was observed for diazenes LV-57, MG-19, JK-429, and JK-913 at high concentrations.

Conclusions:

  • Diazene JK-279 exhibits broad-spectrum cytotoxicity and is a promising candidate for further anticancer drug development.
  • The study highlights the potential of diazenecarboxamides in combating drug-resistant cancers.

Related Concept Videos